



ASX ANNOUNCEMENT

19 January 2009

## Results of VitroGro® Venous Ulcer Human Trial

The final report of the Australian clinical trial of 8 venous ulcer patients treated with VitroGro® twice a week showed a reduction in median\* wound area from 9.2 to 5.2 square centimetres in 24 days. This trial, originally designed as a safety study, was conducted by the clinical research group headed by Professor Michael Stacey at the Vascular Research Laboratory, Fremantle Hospital, Australia.

Additional key findings of this study were:

- Reduction in wound area was highly statistically significant  $p < 0.01$
- VitroGro® is safe and well tolerated

Five females and three males were enrolled in this human trial, with median age of 74 years. The median duration of the venous ulcers treated was 6 months, with a range of 1 to 29 months. The treated ulcers ranged in size from 2.2 to 19.0 square centimetres, with a median size of 9.2 square centimetres.

Four of the eight subjects commenced compression therapy at the start of the study, while the other four had been treated with compression therapy for periods varying from 2 to more than 24 months. Currently, compression therapy is the best practice treatment for venous ulcers.

Since compression therapy was started at the same time as VitroGro® treatment in 4 patients, it is not possible to attribute the healing of these patients solely to the use of VitroGro®. However, the reduction in wound area was highly statistically significant, as noted above. Eleven adverse events were recorded during the study but none were attributed to the VitroGro® treatment.

The CEO of Tissue Therapies, Dr Steven Mercer said, "everyone at Tissue Therapies is delighted with the results of this study. These are consistent with our understanding of how VitroGro® works and give us even more confidence that the larger Canadian study will produce exceptional clinical results."

Patient recruitment is proceeding to plan in Toronto, Canada, for the human trial of VitroGro® for the treatment of diabetic, venous and pressure ulcers, under the direction of international wound care expert, Professor Gary Sibbald. Results are expected from this trial in the first half of 2009.

\* **Median:** 50<sup>th</sup> percentile ie. half the results occur above the median and half occur below. Median is used in preference to average when the results are not distributed in a normal (bell) curve.

Further information:

Dr Steven Mercer  
CEO, Tissue Therapies Limited  
Telephone: +61 (0)7 3839 9938

Email: [s.mercer@tissuetherapies.com](mailto:s.mercer@tissuetherapies.com)

### **About Tissue Therapies Limited**

Tissue Therapies Limited is an Australian company developing biomedical technologies for wound healing, tissue repair and various cell culture applications.

The Company has worldwide exclusive rights to commercialise VitroGro®, a technology developed by tissue engineering experts at the Institute for Health and Biomedical Innovation at QUT for enhancing cell growth and migration. VitroGro® has particular commercial applications in wound healing, tissue regeneration, stem cell therapies and other cell culture uses.

Based on its VitroGro® technology, Tissue Therapies is developing more effective medical treatments for wound healing including chronic ulcers and burns,

Tissue Therapies also provides cell culture reagents to enhance the growth of mammalian cells for emerging cell-based therapies, along with research and industrial cell culture markets internationally.

**More information:** [www.tissuetherapies.com](http://www.tissuetherapies.com)